Moderna announced on Aug. 23 that it has requested emergency use authorization from the Food and Drug Administration (FDA) for its bivalent COVID-19 booster vaccine targeted for the Omicron subvariants BA.4 and BA.5.
The company’s latest so-called bivalent vaccine dose, mRNA-1273.222, targets the BA.4/BA.5 subvariants of the Omicron strain as well as the original strain of SARS-CoV-2 that first emerged in Wuhan, China, in 2019.
